Crossing An Ethical Boundary
By Marcy Darnovsky,
The Journal of Life Sciences
| 05. 19. 2008
What prompted the recent headlines about genetically-modified human embryos? Why did a brief account of an experiment at Cornell University, presented last fall at an American Society for Reproductive Medicine conference and then published without fanfare in its journal Fertility and Sterility, suddenly make news around the world?
The work in question involved transferring a gene that codes for a fluorescing protein into a non-viable human embryo, and showing that all the cells in the embryo glowed after three days of cell division. As one of the research team's members later acknowledged, it was the first time that scientists are known to have created a genetically-modified human embryo.
Strangely, the study stayed beneath the public and media radar for months. It was brought to the attention of the UK's Sunday Times by Dr. David King, director of the British organization Human Genetics Alert, who came across it recently while reading a document prepared by the Human Fertilization and Embryology Authority. The story ran in the May 11 Sunday Times and was then picked up by the Associated Press and...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...